Jeffery N. Talbot, Ph.D.
Director, Research Center on Substance Abuse and Depression

Dr. Jeffery Talbot is the Director of the Research Center on Substance Abuse and Depression at the Roseman University of Health Sciences.  Dr. Talbot received a B.S. in Biochemistry from the University of Nevada before earning a Ph.D. in Pharmacology from the University of Nebraska Medical Center.  He later served as a Post-doctoral Research Fellow in Pharmacology at the University of Michigan Medical School.  Most recently, Dr. Talbot served as an Assistant/Associate Professor at the Ohio Northern University College of Pharmacy.  His research focuses on the discovery and development of psychiatric drugs targeting substance abuse and mood disorders using genetic, in vivo animal models.  His most recent work is a multidisciplinary effort involving researchers from both academia and the National Institutes of Health developing investigational drugs that possess both rapid and sustained antidepressant properties.


John R. Traynor, PhD
Professor of Pharmacology
University of Michigan Medical School
Dr. Traynor is the current president of the International Narcotics Research Conference and the former Director of the University of Michigan Substance Abuse Research Center. He also serves as the Head of the Pharmacology Graduate Program at the University of Michigan. He is a principle investigator of a National Institute on Drug Abuse funded training grant focused on the biology of drug abuse. Prior to joining the University of Michigan, Dr. Traynor earned degrees in Pharmacy (B.S.) and Medicinal Chemistry (Ph.D.), both from the University of Aston in the United Kingdom. His post-doctoral training focused on Biochemical Pharmacology at the University of Gottingen in Germany. For over 25 years, Dr. Traynor’s research has focused on opioids and includes areas such as structure-activity relationships, signaling and behavior. He has trained more than 25 PhD students and 10 postdoctoral fellows as well as many Masters and Undergraduate students. More recently, his attention has focused on a specific family of intracellular proteins (RGS proteins) that act as negative regulators of neurotransmitters such as endorphins, dopamine, and serotonin. The long term aim of these studies is to identify novel targets and medications to treat pain, drug dependence and depression

Jon E. Sprague, RPh, PhD
University Director of Academic Research
Head of Pharmaceutical Sciences
The College of Pharmacy
Ferris State University
Dr. Jon E. Sprague is the University Director of Academic Research and Head of Pharmaceutical Sciences for the College of Pharmacy at Ferris State University. Before joining Ferris State University, he served as Dean and Professor of Pharmacology at the Raabe College of Pharmacy at Ohio Northern University (ONU). Dr. Sprague has also served as Chair and Professor of Pharmacology at the Virginia College of Osteopathic Medicine, Virginia Tech University. He received his PhD. in Pharmacology and Toxicology from Purdue University. He also was on the faculty in the College of Pharmacy at Purdue. His research interests include studying the hyperthermic mechanisms of the substituted amphetamines, namely 3,4-methylene¬dioxy¬meth¬amphetamine (MDMA, Ecstasy) and synthetic cathinones (bath salts). He and his wife (Aimee) have two young children; Emily (19) and Ryan (15).

Christopher R. McCurdy, PhD
Research Professor in the Research Institute of Pharmaceutical Sciences
Professor of Medicinal Chemistry and Pharmacology
The University of Mississippi
Dr. Christopher McCurdy is co-director of the National Institutes of Health Center for Research Excellence in Natural Products for Neurosciences at the University of Mississippi School of Pharmacy. Dr. McCurdy also serves as a full professor, with joint appointments in Medicinal Chemistry and Pharmacology in the Department of Biomolecular Sciences. Before joining the University of Mississippi in 2001, Dr. McCurdy completed a postdoctoral research fellowship at the University of Minnesota under the direction of Distinguished Professor Philip S. Portoghese. His educational background includes degrees earned in Pharmacy (B.S.) from Ohio Northern University and Medicinal Chemistry (Ph.D.) from the University of Georgia.

Dr. McCurdy’s research focuses on developing novel treatments for pain, anxiety, depression and drug addiction, work that is funded by the National Institutes of Health, Centers for Disease Control, National Science Foundation, and the American Association of Colleges of Pharmacy. He has trained many PhD graduate students and postdoctoral fellows and has been recognized with the highest awards in teaching and research from the University of Mississippi. Dr. McCurdy serves on numerous industrial and scientific journal editorial boards as well as various leadership positions with the American Association of Pharmaceutical Scientists (AAPS) and American Association of Colleges of Pharmacy (AACP).

B. Shane Martin, PharmD, BCPP
Clinical Pharmacy Specialist, Mental Health
Chillicothe VA Medical Center
US Department of Veterans Affairs
Dr. Martin is a Clinical Pharmacist in Mental Health at the Chillicothe VA Medical Center. A graduate of The Ohio State University College of Pharmacy, he completed his post-graduate residency training in psychiatry at The Ohio State University Medical Center. Following his residency, Dr. Martin was an Assistant Professor of Pharmacy Practice at the Ohio Northern University College of Pharmacy before joining VAMC in full-time clinical practice.

Donald Sullivan, RPh, PhD
Professor of Clinical Pharmacy
Director of Professional Experiential Programs
Pharmacy Practice and Science
The Ohio State University
Donnie Sullivan is a Professor of Clinical Pharmacy at The Ohio State University College of Pharmacy.  He received his B.S. in pharmacy from Ohio State University in 1990, his MS from Ohio State University in 1991, and his Ph.D. is Pharmacy Administration from Ohio State University in 1996.  He has published several peer-reviewed articles and five consumer drug reference books.  He has taught courses in pharmacy law and drug diversion for 18 years.  He has done more than 100 professional presentations on pharmacy law and drug diversion all across the U.S.  He currently trains DEA, FBI, and Department of Justice employees on drug diversion detection and analysis at the DEA Training Academy in Quantico, VA several times a year.

David B. Rawlins, PhD
Associate Professor of Pharmaceutical Sciences
College of Pharmacy
Roseman University of Health Sciences
Dr. David Rawlins is a medicinal chemist who spent twenty years in the pharmaceutical industry discovering new medications prior to joining Roseman University. He received a B.S. in microbiology and M.S. in chemistry from Brigham Young University followed by a Ph.D. in organic chemistry from Stanford University. He joined Bristol-Myers Squibb and researched ways to treat oncology and immunology related diseases. In 2003, he joined Lexicon Pharmaceuticals where he continued researching in oncology, ophthalmology, and metabolic disorders. His research group has found multiple drugs that entered human clinical trials including sotagliflozin (Zynquista), a novel drug to treat both Type 1 and Type 2 diabetes. Sotagliflozin was listed by the Motley Fool as one of the “Top 12 greatest breakthroughs of 2016” and awarded a 2017 Thomas A. Edison Patent Award in the pharmaceutical category. Dr. Rawlins joined Roseman University of Health Sciences in 2015 as an Assistant Professor of Pharmaceutical Sciences where he not only teaches in the College of Pharmacy, but also continues research into new medications for depression.

Krystal Riccio, PharmD
Associate Professor of Pharmacy Practice
Roseman University of Health Sciences
Faculty Advisor, Drug Abuse Awareness Team
UMC Southern Nevada, Clinical Faculty
Dr. Riccio is an Associate Professor of Pharmacy Practice, within the College of Pharmacy, at Roseman University of Health Sciences. She completed a pharmacy practice residency at the VA Southern Nevada Health Care System and began her academic appointment at Roseman University.  Dr. Riccio currently practices within University Medical Center Primary Care Clinics, where she precepts student pharmacists, and teaches within the classroom across the didactic curriculum.  She also facilitates continuing education programing as faculty within Roseman University’s Continuing Education Department.  As a pharmacy student, Dr. Riccio was a co-founder of the Drug Abuse Awareness Team (DAAT), which focusses on educating middle-high school students about the dangers of over-the-counter and prescription drugs of abuse, coordinating drug-take-back events, and raising community awareness through outreach events within Southern Nevada.  As faculty, she has continued as the faculty advisor for DAAT and is currently working, through the Roseman University Research Center on Substance Abuse and Depression, with nationally recognized experts in the field of adolescent risk behavior surveillance and prevention programming.  Her goal is to bring effective programs to Nevada, which will allow our state to emerge as a leader in identifying and addressing the perceptions and attitudes of our youth surrounding substances of abuse.  Dr.  Riccio actively participated in the Prescription Drug Abuse Academy in 2015, worked in the Education Section and Screening Section of the logic modelling for SB459, and most recently was a panelist within the Provider Education Track at the 2016 Nevada Prescription Drug Abuse Prevention Summit.  She is very passionate about the use of education to combat the problem of addiction in our state and believes we can educate early and often to help our state grow out of this rising epidemic.